Comparative Pharmacology
Head-to-head clinical analysis: FLURAZEPAM HYDROCHLORIDE versus LIMBITROL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLURAZEPAM HYDROCHLORIDE versus LIMBITROL.
FLURAZEPAM HYDROCHLORIDE vs LIMBITROL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Positive allosteric modulator of GABA-A receptors, enhancing the inhibitory effects of GABA by increasing the frequency of chloride channel opening.
Limbitrol is a combination of chlordiazepoxide (a benzodiazepine) and amitriptyline (a tricyclic antidepressant). Chlordiazepoxide enhances GABA-A receptor activity, producing anxiolytic and sedative effects. Amitriptyline inhibits serotonin and norepinephrine reuptake, elevating mood and reducing pain. The combination is used for depression with anxiety.
15-30 mg orally at bedtime as a single dose for insomnia; maximum dose 30 mg/day.
1-2 tablets (5 mg chlordiazepoxide / 12.5 mg amitriptyline per tablet) orally 3-4 times daily. Maximum 6 tablets per day in divided doses.
None Documented
None Documented
Terminal elimination half-life: 40-114 hours (mean 74 hours); accumulates extensively with repeated dosing, leading to prolonged sedation.
Amitriptyline: 20-30 hours (range 10-46 h) with a terminal elimination half-life of ~24 h; clinical significance requires 7-14 days to reach steady state. Chlordiazepoxide: 5-30 hours (up to 48 h for active metabolite desmethylchlordiazepoxide).
Renal: 90% (as metabolites, <1% unchanged); Fecal: <10%; Biliary excretion minimal.
Renal (approximately 70-80% as metabolites, 1-3% unchanged) and fecal (20-30% via biliary elimination for chlordiazepoxide component; amitriptyline is primarily excreted renally as metabolites, 10-15% unchanged).
Category D/X
Category C
Benzodiazepine
Benzodiazepine/Tricyclic Antidepressant Combination